Big pharma, Partnering

Bayer and Isis in ISIS-FXIRx licensing pact

Posted on 05 May 2015

Tags: , ,

Bayer HealthCare has entered into an exclusive license agreement with Isis Pharmaceuticals on ISIS-FXIRx, an antisense investigational drug in clinical development for the prevention of thrombosis.

Under the agreement Bayer will further develop and commercialize ISIS-FXIRx in areas of high unmet medical need.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

As part of the clinical development program, Bayer plans to evaluate the therapeutic profile of ISIS-FXIRx in an appropriate patient community.

Isis is eligible to receive near-term payments, including an up-front payment and payment upon advancement of the program following a Phase II study in patients with compromised kidney function.

Isis is also eligible to receive milestone payments as the drug advances toward the market.

In addition, Isis is eligible to receive tiered royalties on gross margins of ISIS-FXIRx.

After completion of ongoing activities at Isis, Bayer will assume all global clinical development as well as worldwide regulatory and commercialization responsibilities for ISIS-FXIRx.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply